Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Income towards Parent Company: 2009-2024

Historic Income towards Parent Company for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to -$6.4 million.

  • Cumberland Pharmaceuticals' Income towards Parent Company fell 26.81% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.3 million, marking a year-over-year increase of 69.22%. This contributed to the annual value of -$6.4 million for FY2024, which is 1.78% down from last year.
  • As of FY2024, Cumberland Pharmaceuticals' Income towards Parent Company stood at -$6.4 million, which was down 1.78% from -$6.3 million recorded in FY2023.
  • Cumberland Pharmaceuticals' 5-year Income towards Parent Company high stood at $3.3 million for FY2020, and its period low was -$6.4 million during FY2024.
  • In the last 3 years, Cumberland Pharmaceuticals' Income towards Parent Company had a median value of -$6.3 million in 2023 and averaged -$6.1 million.
  • Data for Cumberland Pharmaceuticals' Income towards Parent Company shows a maximum YoY plummeted of 383.31% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Cumberland Pharmaceuticals' Income towards Parent Company stood at $3.3 million in 2020, then tumbled by 40.00% to $2.0 million in 2021, then plummeted by 383.31% to -$5.7 million in 2022, then decreased by 12.05% to -$6.3 million in 2023, then declined by 1.78% to -$6.4 million in 2024.